We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Pfizer (PFE) Stock Drops Despite Market Gains: Important Facts to Note
Read MoreHide Full Article
Pfizer (PFE - Free Report) closed at $27.10 in the latest trading session, marking a -2.62% move from the prior day. The stock's performance was behind the S&P 500's daily gain of 0.08%. Meanwhile, the Dow experienced a drop of 0.18%, and the technology-dominated Nasdaq saw an increase of 0.1%.
Shares of the drugmaker witnessed a gain of 3.8% over the previous month, beating the performance of the Medical sector with its loss of 6.98%, and the S&P 500's loss of 1.74%.
Investors will be eagerly watching for the performance of Pfizer in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on May 5, 2026. It is anticipated that the company will report an EPS of $0.77, marking a 16.3% fall compared to the same quarter of the previous year. Simultaneously, our latest consensus estimate expects the revenue to be $13.83 billion, showing a 0.86% escalation compared to the year-ago quarter.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $2.97 per share and a revenue of $61.01 billion, indicating changes of -7.76% and -2.51%, respectively, from the former year.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Pfizer. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, there's been no change in the Zacks Consensus EPS estimate. Pfizer is holding a Zacks Rank of #3 (Hold) right now.
In the context of valuation, Pfizer is at present trading with a Forward P/E ratio of 9.36. This indicates a discount in contrast to its industry's Forward P/E of 14.22.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This group has a Zacks Industry Rank of 156, putting it in the bottom 37% of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow PFE in the coming trading sessions, be sure to utilize Zacks.com.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Pfizer (PFE) Stock Drops Despite Market Gains: Important Facts to Note
Pfizer (PFE - Free Report) closed at $27.10 in the latest trading session, marking a -2.62% move from the prior day. The stock's performance was behind the S&P 500's daily gain of 0.08%. Meanwhile, the Dow experienced a drop of 0.18%, and the technology-dominated Nasdaq saw an increase of 0.1%.
Shares of the drugmaker witnessed a gain of 3.8% over the previous month, beating the performance of the Medical sector with its loss of 6.98%, and the S&P 500's loss of 1.74%.
Investors will be eagerly watching for the performance of Pfizer in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on May 5, 2026. It is anticipated that the company will report an EPS of $0.77, marking a 16.3% fall compared to the same quarter of the previous year. Simultaneously, our latest consensus estimate expects the revenue to be $13.83 billion, showing a 0.86% escalation compared to the year-ago quarter.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $2.97 per share and a revenue of $61.01 billion, indicating changes of -7.76% and -2.51%, respectively, from the former year.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Pfizer. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, there's been no change in the Zacks Consensus EPS estimate. Pfizer is holding a Zacks Rank of #3 (Hold) right now.
In the context of valuation, Pfizer is at present trading with a Forward P/E ratio of 9.36. This indicates a discount in contrast to its industry's Forward P/E of 14.22.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This group has a Zacks Industry Rank of 156, putting it in the bottom 37% of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow PFE in the coming trading sessions, be sure to utilize Zacks.com.